Last update Oct. 14, 2020
Very High Risk
We do not have alternatives for Teniposide.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Teniposide in other languages or writings:
Teniposide belongs to this group or family:
Main tradenames from several countries containing Teniposide in its composition:
|VD||0.2 - 1.09||l/Kg|
|T½||5 - 5.4||hours|
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
An antineoplastic with properties similar to etoposide, used in the treatment of lymphomas, neuroblastomas and leukemias.
It is administered intravenously in widely varied regimens. Since the last update, we have not found published data on its excretion in breastmilk.
Since the last update, we have not found published data on its excretion in breastmilk.
Its pharmacokinetic data (short half-life and high percentage of protein binding) make it unlikely that significant amounts will transfer into breastmilk.
Given its serious side effects, it is prudent to suspend breastfeeding during the period when the drug is still in the mother's body.
It is known from pharmacokinetics that after 3 elimination half-lives (T½), 87.5% of the drug is eliminated from the body; after 4 T½, 94% is eliminated, 96.9% after 5 T½, 98.4% after 6 T½ and 99% after 7 T½. From 7 T½ the plasma concentrations of the drug in the body are negligible. In general, a period of at least five half-lives can be considered a safe waiting period before breastfeeding again (Anderson 2016).
Taking as reference the longest reported T½ of all active metabolites, these 5 T½ would correspond to 27 hours. Due to major adverse effects, it would be advisable to wait 7 T½, which would correspond to 38 hours. Meanwhile, express and discard breastmilk regularly.
Some authors recommend waiting 48 hours before breastfeeding again (Hale 2017 p 915).
When possible, detections in each patient's milk to determine total drug elimination would be the best indicator for resuming breastfeeding between two cycles of chemotherapy.
Breastfeeding must be discontinued during cancer treatment due to potentially serious side effects for the infant. Chemotherapy does not affect milk production during or after treatment. Abrupt weaning can be psychologically traumatic for both mother and infant (Pistilli 2013).
If the mother wishes, milk production can be maintained by regularly expressing breastmilk, and breastfeeding can occur in periods when there are no significant traces of the drug in breastmilk (Anderson 2016) or at the end of treatment (Pistilli 2013).
Some chemotherapeutic agents with antibiotic effects can alter the composition of the microbiota (group of bacteria or bacterial flora) in milk and the concentration of some of its components (Urbaniak 2014). This possibly occurs temporarily with subsequent recovery, without any harmful effects being recorded in breastfed infants.
Women in chemotherapy during pregnancy have lower breastfeeding rates due to difficulties with breastfeeding (Stopenski 2017), needing more support to achieve it.
Given the amount of evidence that exists on the benefits of breastfeeding for the development of babies and the health of mothers, it is advisable to assess the risk-benefit of any maternal treatment, including chemotherapy, individually advising each mother who wishes to continue with breastfeeding (Koren 2013).
See below the information of this related product: